Navigation Links
CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
Date:6/4/2008

VIENNA, Va., June 4 /PRNewswire-FirstCall/ -- In response to numerous shareholder questions, CEL-SCI CORPORATION (Amex: CVM) is providing an update on the construction of its manufacturing facility near Baltimore, Maryland. The facility, when fully built out, will comprise 73,000 square feet and will be used to manufacture Multikine(R), the Company's lead cancer product. This dedicated facility will produce the Multikine that will be used for CEL-SCI's pivotal Phase III clinical trial for first-line therapy of previously untreated head and neck cancer patients, and subsequently for sale following approval of the drug.

Upon completion of the first phase of the build out (28,000 square feet) in the 2008 third quarter, the facility will be capable of supporting approximately $600 million of annual commercial sales of Multikine. The facility build out is currently about 70% complete. The facility is being developed for CEL-SCI by BioRealty, Inc. (http://www.biorealty.com) and the design builder is BE&K, Inc. (http://www.bek.com/index.asp). Pictures of the manufacturing facility, located close to Baltimore, MD, can be accessed on CEL-SCI's website at http://www.cel-sci.com under "Special Highlights", "Pictures of Manufacturing Facility".

"CEL-SCI has been advised by BE&K that the manufacturing facility is on target to be completed on schedule," said Geert Kersten, CEL-SCI's Chief Executive Officer. "The facility will provide CEL-SCI with tight control over the Multikine manufacturing process, eliminating key risks to the successful completion of the pivotal Phase III trial
'/>"/>

SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. BioElectronics Corporation Announces Singapore and Malaysia Sales
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
9. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
10. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., , COPENHAGEN, Nov. 19 Danish...bicon cellulosic ethanol plant in Kalundborg, Denm...e of the world,s first and largest 2nd generation ...cellerase enzymes are used in the plant,s innovati... a Division of Danisco, was the first to market wi...
(Date:11/19/2009)..., , NEW YORK, Nov. 19 /PRNewswire-FirstCall/ ...ay that it has sent the following letter to its sh...on October 30, 2009, of China Biopharmaceuticals H...ical company based in the People,s Republic of Chi...erest in Suzhou Eyre Pharmaceutical Co. Ltd., CHBP...
(Date:11/19/2009)..., , MONTREAL, Nov. 19 /PRNewswire/ - Aegera T... first patient in a randomized Phase 2B study of A...tage development for multiple oncology indications...zed Phase 2 Study of the X-Linked Inhibitor of Apo...ion with High-dose Cytarabine and Idarubicin in AM...
(Date:11/19/2009)..., , VIENNA, Austria, November 19 /PRN...vaccine program on one product candidate at an une...candidate AD02 is planned to enter into,Phase II c...company,immediately follows the completion of two ...The company based its fast decision on the first i...
Breaking Biology Technology:DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...dge, Highlight Most Recent ...Educators, an accredited,provider of continuing ed...,of three talented individuals to its staff. Backe...egrees in molecular biology, structural biology,bi...m the top universities,across the nation, each bri...
...asdaq: NEOG ) announced today that its net income.... 31, increased 25% from the previous year,s first...ck split, net income per,share was $0.21 in the fi...ame period in the prior year. First quarter reven...0,to $22,909,000 -- representing a record for reve...
...nc. (Amex: ANX ), a biopharmaceutical research an...roprietary product candidates for the treatment,of...hat data from,preclinical studies of ANX-514 (doce...Association of Cancer Research (AACR), National Ca... Treatment of Cancer (EORTC),International Confere...
Other Biology Technology:ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 2ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 3Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 2Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 3Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 4Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 5ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4
(Date:11/20/2009)...all read studies about the health benefits of havi...olecular level, where amino acids known as cystein...than when paired up with other cysteines. , Now,...with colleagues in Belgium, have discovered a new ... The research appears in the Nov. 20 issue of the ...
(Date:11/20/2009)...0, 2009) Scientists from the Marine Biogeochemist...l Research Laboratory (NRL) organized and led a te...rctic expedition to initiate methane hydrate explo...al variation of sediment contribution to Arctic cl...utter Polar Sea as a research platform, three cros...
(Date:11/20/2009)...a single bacterial gene into yeast, researchers fr...ds achieved three improvements in bioethanol produ...nol, less acetate and elimination of the major by-...ished in the scientific journal Applied and Envir...nol is made by the yeast Saccharomyces cerevisiae ...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2International expedition investigates climate change, alternative fuels in Arctic 2Delft breakthrough in bioethanol production from agricultural waste 2ThermoGenesis Provides Update on Fiscal 2009 Results 13429 1ThermoGenesis Provides Update on Fiscal 2009 Results 13429 2ThermoGenesis Provides Update on Fiscal 2009 Results 13429 3ThermoGenesis Provides Update on Fiscal 2009 Results 13429 4ThermoGenesis Provides Update on Fiscal 2009 Results 13429 5OncoGenex Reports Second Quarter 2009 Financial Results 13426 1OncoGenex Reports Second Quarter 2009 Financial Results 13426 2OncoGenex Reports Second Quarter 2009 Financial Results 13426 3OncoGenex Reports Second Quarter 2009 Financial Results 13426 4OncoGenex Reports Second Quarter 2009 Financial Results 13426 5OncoGenex Reports Second Quarter 2009 Financial Results 13426 6OncoGenex Reports Second Quarter 2009 Financial Results 13426 7Combo Treatment May Ease Depression After Stroke 53891 1Combo Treatment May Ease Depression After Stroke 53891 2
... 4, 2008 Researchers at UT Southwestern Medical C...od to screen small synthetic molecules and pull ou...ases less expensively than current methods. , In ...lled peptoids, the new technique quickly singled o...body already on the market for treating cancer. On...
... the Burnham Institute for Medical Research (Burnh...t of a disorder called Sporadic Inclusion Body Myo...s predominantly older men, causing muscles to grad...living with sIBM is unknown, but it is the most co..., and due to its unfamiliarity, it is probably und...
... have noticed that their four-legged friend seem e...ay as five hours, may wonder if animals can tell w... University of Western Ontario in London, Canada m.... , The results of the research, entitled Episodi...Long Ago, appear in the current issue of the journ...
Other Biology News:Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 2Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 3RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Are animals stuck in time? 2
...ing a protein engineering approach that introduced... wild-type DNase I. These changes markedly increas...is a versatile enzyme that has a 6-fold lower Km f... peak activity in solutions approaching 200 mM mon...
iTaq DNA Polymerase, 250 U from Bio-Rad
Rabbit Anti-hnRNP U Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
...tages in your laboratory or fellow researchers wan...distractions, problems and delays. • Rece...ing us your idea and let us build it up and market...y assurance in design, development, production, in...
Biology Products: